Status:
ACTIVE_NOT_RECRUITING
Evaluation of Prevalence and Risk Factors of Persistent COVID-19 in Immunocompromised Patients
Lead Sponsor:
Maddalena Giannella
Conditions:
Persistent COVID-19
B Cell Malignancies
Eligibility:
All Genders
18+ years
Brief Summary
Spontaneous international multicenter retrospective and prospective observational study which objective is to evaluate the prevalence and risk factors of persistent SARS-CoV-2 infection within a popul...
Detailed Description
Spontaneous international multicenter retrospective and prospective observational study which objective is to evaluate the prevalence and risk factors of persistent SARS-CoV-2 infection within a popul...
Eligibility Criteria
Inclusion
- Diagnosis of B cell malignancies or previous treatment with B cell targeting therapies.
- Diagnosis of proven SARS-CoV-2 infection confirmed by a PCR test (only the first infection during the study period will be considered, re-infection will be counted as a secondary endpoint).
- Provision of signed and dated informed consent.
Exclusion
- None
Key Trial Info
Start Date :
March 1 2024
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
September 30 2025
Estimated Enrollment :
204 Patients enrolled
Trial Details
Trial ID
NCT06576102
Start Date
March 1 2024
End Date
September 30 2025
Last Update
March 27 2025
Active Locations (5)
Enter a location and click search to find clinical trials sorted by distance.
1
Irccs Aoubo
Bologna, Italy, 40138
2
IRCCS Humanitas
Milan, Italy, 20089
3
IRCCS INMI L. Spallanzani
Roma, Italy, 00149
4
AOUI Verona
Verona, Italy, 37126